Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

5-MeO-T-NB3OMe

From Wikipedia, the free encyclopedia

Pharmaceutical compound
5-MeO-T-NB3OMe
Clinical data
Other names5MT-NB3OMe; NB3MeO-5-MeO-T; 5-MeO-T-NB3MeO; 5-MeO-NB3OMeT;N-(3-Methoxybenzyl)-5-methoxytryptamine
Drug classSerotonin receptor modulator;Serotonin 5-HT2A receptor agonist;Serotonergic psychedelic;Hallucinogen
ATC code
  • None
Identifiers
  • 2-(5-methoxy-1H-indol-3-yl)-N-[(3-methoxyphenyl)methyl]ethanamine
CAS Number
PubChemCID
ChemSpider
Chemical and physical data
FormulaC19H22N2O2
Molar mass310.397 g·mol−1
3D model (JSmol)
  • COC1=CC2=C(C=C1)NC=C2CCNCC3=CC(=CC=C3)OC
  • InChI=1S/C19H22N2O2/c1-22-16-5-3-4-14(10-16)12-20-9-8-15-13-21-19-7-6-17(23-2)11-18(15)19/h3-7,10-11,13,20-21H,8-9,12H2,1-2H3
  • Key:CJLDIVRTIQMENX-UHFFFAOYSA-N

5-MeO-T-NB3OMe, or5MT-NB3OMe, also known asN-(3-methoxybenzyl)-5-methoxytryptamine, is aserotonin receptor modulator andpsychedelic drug of thetryptamine,5-methoxytryptamine, andN-benzyltryptamine families related to the25-NB (NBOMe) psychedelics.[1][2][3][4] It is apositional isomer of5-MeO-T-NBOMe (5-MeO-T-NB2OMe).[2]

The drug showsaffinity for manyserotonin receptors and acts as anagonist of theserotonin5-HT2A,5-HT2B, and5-HT2C receptors.[4] It had similar affinity andactivationalpotency at the human serotonin 5-HT2A receptor as 5-MeO-T-NBOMe.[4] In addition, the drug had around 10-fold lower affinity for the human serotonin 5-HT2A receptor as25I-NBOMe (25I-NB2OMe) but showed similar activational potency at this receptor as 25I-NBOMe.[4] 5-MeO-T-NB3OMe produces thehead-twitch response, a behavioral proxy of psychedelic effects, in rodents.[2][4] It had similar potency in this test as 5-MeO-T-NBOMe and25I-NB3OMe, but showed dramatically or 42- to 45-fold lower potency than 25I-NBOMe.[2][4]

Thechemical synthesis of 5-MeO-T-NB3OMe has been described.[4] Variousanalogues of 5-MeO-T-NB3OMe besides 5-MeO-T-NBOMe have also been described.[2][4][5][6]

5-MeO-T-NB3OMe was first described in thescientific literature byDavid E. Nichols and colleagues in 2015.[1][2][3][4] It is not acontrolled substance inCanada as of 2025.[7] It is also not an explicitlycontrolled substance in theUnited States,[8] but it could be considered a controlled substance under theFederal Analogue Act if intended for human consumption.

See also

[edit]

References

[edit]
  1. ^abDuan W, Cao D, Wang S, Cheng J (January 2024). "Serotonin 2A Receptor (5-HT2AR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants".Chemical Reviews.124 (1):124–163.doi:10.1021/acs.chemrev.3c00375.PMID 38033123.Interestingly, a study around a series of N-benzylated-5- methoxytryptamine analogues (Figure 7C) revealed that benzyl substitution led to compounds with very high affinity at the 5-HT2 family receptors.151 Various substituents on the phenyl group were well tolerated, but ortho and meta substitutions generally provided more potent compounds compared to the para substituted analogues (57−66, Figure 7C). Among them, compounds 65 (2-OMe) and 59 (3-OMe) displayed strong affinity at the h5-HT2AR (Ki = 1.51 and 1.05 nM, respectively; [ 125I]-DOI) as very potent partial agonists in the calcium flux assay (EC50 = 1.9 nM (Emax = 81%) and 6.2 nM (Emax = 52%), respectively). More importantly, compounds 65 and 59 were also tested in the HTR experiment, and they exhibited potent hallucinogenic effects with ED50 values of 3.15 nM and 3.28 nM, respectively.151 However, compounds 65 and 59 could also bind very potently to the 5- HT2CR (Ki = 3.39 nM and 5.89 nM, respectively) and the 5- HT2BR (Ki = 9 nM and 2.5 nM, respectively),151 therefore lacking subtype-selectivity for the 5-HT2AR.
  2. ^abcdefHalberstadt AL, Geyer MA (2018). "Effect of Hallucinogens on Unconditioned Behavior".Behavioral Neurobiology of Psychedelic Drugs. Curr Top Behav Neurosci. Vol. 36. pp. 159–199.doi:10.1007/7854_2016_466.ISBN 978-3-662-55878-2.PMC 5787039.PMID 28224459.
  3. ^abBrandt SD, Elliott SP, Kavanagh PV, Dempster NM, Meyer MR, Maurer HH, et al. (April 2015)."Analytical characterization of bioactive N-benzyl-substituted phenethylamines and 5-methoxytryptamines"(PDF).Rapid Communications in Mass Spectrometry.29 (7):573–584.Bibcode:2015RCMS...29..573B.doi:10.1002/rcm.7134.PMID 26212274.
  4. ^abcdefghiNichols DE, Sassano MF, Halberstadt AL, Klein LM, Brandt SD, Elliott SP, et al. (July 2015)."N-Benzyl-5-methoxytryptamines as Potent Serotonin 5-HT2 Receptor Family Agonists and Comparison with a Series of Phenethylamine Analogues".ACS Chemical Neuroscience.6 (7):1165–1175.doi:10.1021/cn500292d.PMC 4505863.PMID 25547199.
  5. ^Toro-Sazo M, Brea J, Loza MI, Cimadevila M, Cassels BK (2019)."5-HT2 receptor binding, functional activity and selectivity in N-benzyltryptamines".PLOS ONE.14 (1) e0209804.Bibcode:2019PLoSO..1409804T.doi:10.1371/journal.pone.0209804.PMC 6328172.PMID 30629611.
  6. ^WO 2023070228A1, Bryson N, "Novel benzyltryptamine compounds", published May 2023, assigned to Reunion Neuroscience Canada Inc. 
  7. ^"Controlled Drugs and Substances Act".Department of Justice Canada. Retrieved19 January 2026.
  8. ^Orange Book: List of Controlled Substances and Regulated Chemicals (January 2026)(PDF),United States: U.S.Department of Justice:Drug Enforcement Administration (DEA): Diversion Control Division, January 2026

External links

[edit]
Tryptamines
No ring subs.
4-Hydroxytryptamines
5-Hydroxytryptamines
5-Methoxytryptamines
Other ring subs.
α-Alkyltryptamines
Others
Cyclized
Bioisosteres
Phenethylamines
Scalines
2C-x
3C-x
DOx
4C-x
Ψ-PEA
MDxx
FLY
25x-NB (NBOMes)
Others
Cyclized
Lysergamides
Others
Natural sources
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Tryptamines
4-Hydroxytryptamines
andesters/ethers
5-Hydroxy- and
5-methoxytryptamines
N-Acetyltryptamines
α-Alkyltryptamines
α-Ketotryptamines
Cyclized tryptamines
Isotryptamines
Related compounds
Retrieved from "https://en.wikipedia.org/w/index.php?title=5-MeO-T-NB3OMe&oldid=1334213513"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2026 Movatter.jp